Vorasidenib · Voranigo, AG-881

What is Vorasidenib?

Vorasidenib is a small molecule inhibitor of mutant isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2). It decreases production of the oncometabolite 2-hydroxyglutarate and restores cellular differentiation in tumors with IDH mutations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Voranigo, AG-881, AGI 23088, AGI 0023088

Drug type

Small molecule

Targets

isocitrate dehydrogenase-1 (IDH1), isocitrate dehydrogenase-2 (IDH2)

Mechanism

Inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2)

Pathways

2-hydroxyglutarate production, cellular differentiation, cellular proliferation

Therapy area

Oncology

Developer

Servier

In trials of

AGIO

FDA status

Approved as Voranigo (August 6, 2024), NDA218784 · FDA label

UNII

789Q85GA8P

✅ FDA-approved uses

• Grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutation

From the indications section of the FDA label (version of Jun 19, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Male ParticipantsHealthy Volunteers

Other drugs acting on IDH1 / IDH2

Sources

• FDA label (DailyMed)
• FDA label Voranigo (2026-06-19), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT03960502

Updated Oct 3, 2026.